利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.012 秒)

    CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION
    4.
    发明公开
    CONDITIONING FOR ALLOGENEIC STEM CELL TRANSPLANTATION 失效
    BEHANDLUNG ZUR ALLOGENEN STAMMZELLTRANSPLANTATION

    公开(公告)号：EP1011694A4

    公开(公告)日：2000-11-15

    申请号：EP97949457

    申请日：1997-11-14

    申请人： BAXTER INT ,  HADASIT MED RES SERVICE

    发明人： SLAVIN SHIMON

    IPC分类号： A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K38/00 ,  A61P43/00 ,  C12N5/0783 ,  C12N5/0789

    CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0647

    摘要： Serious hematologic malignancies are treated through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) treatment regimens involve the elimination of both the patient's hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient's T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin). After this, a donor-derived allogeneic stem cell preparation is administered to the patient. Patients treated according to the claimed invention develop donor-specific unresponsiveness and relatively fewer complications as compared to standard M/L conditioning regimens. The claimed methodologies should prove useful in the treatment of a number of hematologic malignancies such as chronic myelogenous leukemia, acute myelogenous leukemia, acute lymphoblastic leukemia, and non-Hodgkin's lymphoma.

    摘要翻译： 本发明的特征在于在适应性干细胞移植之前调理患者的方法。 第一种方法涉及用淋巴消融方案治疗患者，所述方案使患者的造血干细胞的功能群恢复。 第二种方法涉及用清髓疗法治疗患者，相反，患者的T淋巴细胞群体的功能群体保留。 在两种方法中，患者在调理方案后施用来自供体的干细胞制剂以诱导宿主抗供体无应答。 患者也可以施用同种异体细胞疗法。 本发明还提供了制备患者特异性异基因干细胞制剂的方法。